- Home
- GPRE vs OCEAW Comparison
GPRE vs OCEAW Comparison
Compare GPRE & OCEAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRE
- OCEAW
- Stock Information
- Founded
- GPRE 2004
- OCEAW N/A
- Country
- GPRE United States
- OCEAW United States
- Employees
- GPRE N/A
- OCEAW 7
- Industry
- GPRE Major Chemicals
- OCEAW Biotechnology: Pharmaceutical Preparations
- Sector
- GPRE Industrials
- OCEAW Health Care
- Exchange
- GPRE Nasdaq
- OCEAW Nasdaq
- Market Cap
- GPRE N/A
- OCEAW N/A
- IPO Year
- GPRE N/A
- OCEAW 2021
- Fundamental
- Price
- GPRE $6.18
- OCEAW $0.03
- Analyst Decision
- GPRE Strong Buy
- OCEAW
- Analyst Count
- GPRE 8
- OCEAW 0
- Target Price
- GPRE $22.79
- OCEAW N/A
- AVG Volume (30 Days)
- GPRE 2.1M
- OCEAW N/A
- Earning Date
- GPRE 02-07-2025
- OCEAW N/A
- Dividend Yield
- GPRE N/A
- OCEAW N/A
- EPS Growth
- GPRE N/A
- OCEAW N/A
- EPS
- GPRE N/A
- OCEAW N/A
- Revenue
- GPRE $2,458,796,000.00
- OCEAW N/A
- Revenue This Year
- GPRE $13.10
- OCEAW N/A
- Revenue Next Year
- GPRE $14.96
- OCEAW N/A
- P/E Ratio
- GPRE N/A
- OCEAW N/A
- Revenue Growth
- GPRE N/A
- OCEAW N/A
- 52 Week Low
- GPRE $5.96
- OCEAW N/A
- 52 Week High
- GPRE $24.04
- OCEAW N/A
- Technical
- Relative Strength Index (RSI)
- GPRE 27.08
- OCEAW N/A
- Support Level
- GPRE $5.96
- OCEAW N/A
- Resistance Level
- GPRE $7.00
- OCEAW N/A
- Average True Range (ATR)
- GPRE 0.60
- OCEAW 0.00
- MACD
- GPRE -0.08
- OCEAW 0.00
- Stochastic Oscillator
- GPRE 7.69
- OCEAW 0.00
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.